Tulinercept Biosimilar Fusion Protein (TNF-α) for Research

Cat No.: GMP-Bios-INN-1036

Pre-Made Tulinercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tulinercept is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc), for inhibiting TNF alpha.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1036-1mg 1mg 3090
GMP-Bios-INN-1036-10mg 10mg
GMP-Bios-INN-1036-100mg 100mg
GMP-Bios-INN-1036-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Tulinercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F
INN Name Tulinercept
TargetTNF
FormatFusion Protein
Derivationhuman
Species Reactivityhuman
CH1 IsotypeFusion - [TNFRSF1B (tumor necrosis factor receptor (TNFR) superfamily member 1B, TNFBR, p75, CD120b)]2 - IGHG1 Fc (Fragment constant)
VD LCFusion - [TNFRSF1B (tumor necrosis factor receptor (TNFR) superfamily member 1B, TNFBR, p75, CD120b)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesProtalix Biotherapeutics (Carmiel Israel)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0